Anixa Biosciences CEO Kumar Amit purchased 3,000 shares at $2.75 each, an open-market transaction recorded on September 10, 2026. The purchase left Amit with 665,000 shares, while the transaction represented about 0.5% of his resulting holding, giving investors a precise view of the executive’s post-purchase position.
Key Highlights
- Kumar Amit held 665,000 Anixa Biosciences shares after the transaction.
- The purchase represented about 0.5% of his resulting shareholding.
- The transaction was reported under SEC transaction code P.
Anixa Biosciences Inc (NASDAQ: ANIX) Chief Executive Officer Kumar Amit purchased 3,000 shares at $2.75 per share. The transaction was recorded on September 10, 2026, and classified under code P.
CEO’s Post-Purchase Holding Reaches 665,000 Shares
His ownership stood at 665,000 shares after the purchase. The transaction represented about 0.5% of that resulting holding. The percentage is tied specifically to Amit’s post-transaction share position. The purchase price was stated on a per-share basis. The reported transaction involved Anixa Biosciences shares, with Amit named as the purchaser. The resulting holding figure reflects the shares owned after the transaction was completed.
FAQs
Q: How many Anixa Biosciences shares did Kumar Amit buy?
A: Kumar Amit bought 3,000 Anixa Biosciences shares at $2.75 per share. The purchase was reported under SEC transaction code P.
Q: What was Kumar Amit’s Anixa Biosciences shareholding after the purchase?
A: Following the purchase, Kumar Amit owned 665,000 Anixa Biosciences shares. The filing states that the 3,000-share transaction represented about 0.5% of his resulting shareholding.
Q: When did the Anixa Biosciences CEO buy the shares?
A: Kumar Amit’s Anixa Biosciences share purchase took place on September 10, 2026. The transaction involved 3,000 shares priced at $2.75 each.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.